Verastem Inc.

(VSTM) Trade

By |

Profile

Verastem Oncology is a part of the healthcare sector. It is a commercial-stage company focused on discovering and developing drugs to aid patients suffering from cancer. The company's first commercial product, COPIKTRA (duvelisib) is indicated for the treatment of adult patients with relapsed or refractory chronic lymphocytic leukemia/small lymphocytic lymphoma after at least two prior therapies and relapsed or refractory follicular lymphoma after at least two prior systemic therapies. The Company's product pipeline candidate, defactinib, is a focal adhesion kinase inhibitor in development for the treatment of cancers where there are limited treatment options, including lung, ovarian, lymphoma, pancreatic and other advanced cancers.

Contact Information

Website: www.verastem.com
Email: info@verastem.com
Main Phone: +1 781 292-4200
Address: 117 Kendrick Street
Address 2: Suite 500
State: MA
City / Town: Needham
Country: USA
Postal Code: 02494

Issuer Information

Exchange: NSD
CEO: Brian M. Stuglik
Employees: 169
NAICS: Pharmaceutical Preparation Manufacturing(325412)

Equities News

View More

Profile

Verastem Oncology is a part of the healthcare sector. It is a commercial-stage company focused on discovering and developing drugs to aid patients suffering from cancer. The company's first commercial product, COPIKTRA (duvelisib) is indicated for the treatment of adult patients with relapsed or refractory chronic lymphocytic leukemia/small lymphocytic lymphoma after at least two prior therapies and relapsed or refractory follicular lymphoma after at least two prior systemic therapies. The Company's product pipeline candidate, defactinib, is a focal adhesion kinase inhibitor in development for the treatment of cancers where there are limited treatment options, including lung, ovarian, lymphoma, pancreatic and other advanced cancers.

Contact Information

Website: www.verastem.com
Email: info@verastem.com
Main Phone: +1 781 292-4200
Address: 117 Kendrick Street
Address 2: Suite 500
State: MA
City / Town: Needham
Country: USA
Postal Code: 02494

Issuer Information

Exchange: NSD
CEO: Brian M. Stuglik
Employees: 169
NAICS: Pharmaceutical Preparation Manufacturing(325412)

Equities News

View More
$ 1.41 $ 0.035 (2.55%)
Last Price 1.41 Change $ 0.035 Change % 2.55 Tick N/A
Bid 1.38 Bid Size 100.00 Ask 1.42 Ask Size 1,800.00
Open 1.42 High 1.42 Low 1.35 Prev Close 1.37
Last Trade Volume 940,421 52 Wk Hi 4.58 52 Wk Low 0.83
Market Cap 104.5 mi Ex-Div Date N/A Div Rate N/A Yield N/A
Shares 74,349,659.00 EPS (TTM) -1.88 PE Ratio N/A Exchange NSD
  Last 3 Mo Last 12 Mo
Number of Insider Trades 2 3
Number of Buys 2 3
Number of Sells 0 0
Net Activity 10700 71238
Last 10 Buys Shares
Steven H. Bloom 1,000
Joseph M. Lobacki 1,000
Timothy J. Barberich 1,000
Timothy J. Barberich 1,000
Monica Kleinman 1,000
John B. Green 1,000
Robert Forrester 1,000
John B. Green 1,000
Daniel Paterson 1,000
Robert Forrester 1,000
Last 10 Sell Shares
N/A 0
  Current 1 Week Ago 2 Weeks Ago 3 Weeks Ago
High Target Price Estimate 17 17 17 17
Low Target Price Estimate 7 7 7 7
Mean Target Price Estimate 13.14 13.14 13.14 13.14
Standard Deviation 3.72 3.72 3.72 3.72
Date of Most Recent Estimate 05/31/18 05/22/18 05/22/18 05/31/18
  Current 1 Month Ago 2 Months Ago 3 Months Ago
Strong Buy 6 6 5 5
Moderate Buy 1 1 1 1
Hold 0 0 0 0
Moderate Sell 0 0 0 0
Strong Sell 0 0 0 0
Mean Rec. 1.14 1.14 1.17 1.17